Skip to main content
Caplight Logo









Nuance Pharma

Nuance Pharma

Private
ShanghaiHealthcare & Life Scienceshttps://nuancepharma.com/

Last Round

Series E

Jul 22, 2025

Est. Valuation

$620.7M

Total Funding Raised

$216M

Company Overview

Nuance Pharma is a specialty pharmaceutical company that develops and commercializes innovative therapies for respiratory, emergency care, iron deficiency anemia, and pain management.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug commercializationclinical trialsrespiratory therapyallergy treatmentNMPAin-licensingdrug developmentGreater China marketinvestigational new drugINDpharma bridgemarket accessspecialty pharmacross-border pharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuance Pharma Comparables

Compare Nuance Pharma with similar companies based on industry and business-model similarity.

Nuance Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SciClone Pharmaceuticals (Holdings) Limited
70%
Zai Lab Limited
69%
Stallergenes Greer
67%

Nuance Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EJul 22, 2025
StrategicJun 10, 2021
Series DDec 8, 2020
Series BJun 27, 2018

Key People

Founding team and executive leadership

沈云波

Chief Financial Officer

Executive Team

Charlie Chen

Chief Operating Officer

Executive Team

Nuance Pharma Investors

Notable investors and investment history

Nuance Pharma investors
InvestorRounds
CBC GroupSeries D, Series B
HBM Healthcare InvestmentsSeries D, Series B
MPCSeries D
RTW InvestmentsSeries D
nebag agSeries B
HBM PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2024

    Ohtuvayre launched via early access in Hainan Boao Pilot Zone.

  • Jun 10, 2021

    $15M raised with Verona Pharma plc

Nuance Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuance Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuance Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range23
Year Founded2014
Last FundingJul 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?